These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 19007378)
1. Chemosensitization of gemcitabine-resistant human bladder cancer cell line both in vitro and in vivo using antisense oligonucleotide targeting the anti-apoptotic gene, clusterin. Muramaki M; So A; Hayashi N; Sowery R; Miyake H; Fujisawa M; Gleave ME BJU Int; 2009 Feb; 103(3):384-90. PubMed ID: 19007378 [TBL] [Abstract][Full Text] [Related]
2. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy. Sowery RD; Hadaschik BA; So AI; Zoubeidi A; Fazli L; Hurtado-Coll A; Gleave ME BJU Int; 2008 Aug; 102(3):389-97. PubMed ID: 18336596 [TBL] [Abstract][Full Text] [Related]
3. Knockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine chemotherapy by ERK1/2 inactivation. Tang Y; Liu F; Zheng C; Sun S; Jiang Y J Exp Clin Cancer Res; 2012 Sep; 31(1):73. PubMed ID: 22967941 [TBL] [Abstract][Full Text] [Related]
4. Synergistic antitumor activity by combined treatment with gemcitabine and antisense oligodeoxynucleotide targeting clusterin gene in an intravesical administration model against human bladder cancer kotcc-1 cells. Miyake H; Eto H; Hara I; So A; Li D; Gleave ME J Urol; 2004 Jun; 171(6 Pt 1):2477-81. PubMed ID: 15126879 [TBL] [Abstract][Full Text] [Related]
5. sCLU as prognostic biomarker and therapeutic target in osteosarcoma. Ma J; Gao W; Gao J Bioengineered; 2019 Dec; 10(1):229-239. PubMed ID: 31117872 [TBL] [Abstract][Full Text] [Related]
6. Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo. So A; Sinnemann S; Huntsman D; Fazli L; Gleave M Mol Cancer Ther; 2005 Dec; 4(12):1837-49. PubMed ID: 16373699 [TBL] [Abstract][Full Text] [Related]
7. Antisense oligonucleotide against clusterin regulates human hepatocellular carcinoma invasion through transcriptional regulation of matrix metalloproteinase-2 and E-cadherin. Chen D; Wang Y; Zhang K; Jiao X; Yan B; Liang J Int J Mol Sci; 2012; 13(8):10594-10607. PubMed ID: 22949882 [TBL] [Abstract][Full Text] [Related]
8. Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model. Kususda Y; Miyake H; Gleave ME; Fujisawa M Br J Cancer; 2012 Jun; 106(12):1945-52. PubMed ID: 22588555 [TBL] [Abstract][Full Text] [Related]
9. Secreted clusterin gene silencing enhances chemosensitivity of a549 cells to cisplatin through AKT and ERK1/2 pathways in vitro. Zhang B; Zhang K; Liu Z; Hao F; Wang M; Li X; Yin Z; Liang H Cell Physiol Biochem; 2014; 33(4):1162-75. PubMed ID: 24751980 [TBL] [Abstract][Full Text] [Related]
10. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. Chi KN; Eisenhauer E; Fazli L; Jones EC; Goldenberg SL; Powers J; Tu D; Gleave ME J Natl Cancer Inst; 2005 Sep; 97(17):1287-96. PubMed ID: 16145049 [TBL] [Abstract][Full Text] [Related]
11. Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors. Liu T; Liu PY; Tee AE; Haber M; Norris MD; Gleave ME; Marshall GM Eur J Cancer; 2009 Jul; 45(10):1846-54. PubMed ID: 19342222 [TBL] [Abstract][Full Text] [Related]
12. Synergistic chemsensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. Miyake H; Hara I; Kamidono S; Gleave ME Clin Cancer Res; 2001 Dec; 7(12):4245-52. PubMed ID: 11751526 [TBL] [Abstract][Full Text] [Related]
13. siRNA-directed clusterin silencing promotes cisplatin antitumor activity in human non-small cell lung cancer xenografts in immunodeficient mice. Zhang B; Liu ZM; Hao FG; Wang M Eur Rev Med Pharmacol Sci; 2014 Jun; 18(11):1595-601. PubMed ID: 24943969 [TBL] [Abstract][Full Text] [Related]
14. Secreted clusterin (sCLU) regulates cell proliferation and chemosensitivity to cisplatin by modulating ERK1/2 signals in human osteosarcoma cells. Huang H; Wang L; Li M; Wang X; Zhang L World J Surg Oncol; 2014 Aug; 12():255. PubMed ID: 25106434 [TBL] [Abstract][Full Text] [Related]
15. Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells. Kamada M; So A; Muramaki M; Rocchi P; Beraldi E; Gleave M Mol Cancer Ther; 2007 Jan; 6(1):299-308. PubMed ID: 17218637 [TBL] [Abstract][Full Text] [Related]
16. Effect of Targeting Clusterin Using OGX-011 on Antitumor Activity of Temsirolimus in a Human Renal Cell Carcinoma Model. Nishikawa M; Miyake H; Gleave M; Fujisawa M Target Oncol; 2017 Feb; 12(1):69-79. PubMed ID: 27526062 [TBL] [Abstract][Full Text] [Related]
17. Knockdown of RRM1 with Adenoviral shRNA Vectors to Inhibit Tumor Cell Viability and Increase Chemotherapeutic Sensitivity to Gemcitabine in Bladder Cancer Cells. Zhang X; Taoka R; Liu D; Matsuoka Y; Tohi Y; Kakehi Y; Sugimoto M Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921102 [TBL] [Abstract][Full Text] [Related]
18. sCLU regulates cisplatin chemosensitivity of lung cancer cells in vivo. Ma G; Cai H; Gao L; Wang M; Wang H World J Surg Oncol; 2015 Feb; 13():80. PubMed ID: 25884382 [TBL] [Abstract][Full Text] [Related]
19. Induction of clusterin by AKT--role in cytoprotection against docetaxel in prostate tumor cells. Zhong B; Sallman DA; Gilvary DL; Pernazza D; Sahakian E; Fritz D; Cheng JQ; Trougakos I; Wei S; Djeu JY Mol Cancer Ther; 2010 Jun; 9(6):1831-41. PubMed ID: 20501799 [TBL] [Abstract][Full Text] [Related]
20. Targeting Clusterin Induces Apoptosis, Reduces Growth Ability and Invasion and Mediates Sensitivity to Chemotherapy in Human Osteosarcoma Cells. Wang X; Yu Y; Zang L; Zhang P; Ma J; Chen D Curr Pharm Biotechnol; 2020; 21(2):131-139. PubMed ID: 31433751 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]